Research To Practice | Oncology Videos Research To Practice

Featuring perspectives from Dr Andrew J Armstrong and Ms Brenda Martone, including the following topics:
Introduction: Overview of Prostate Cancer; Hormonal Therapy (0:00) Radiopharmaceuticals for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) (24:11) Biomarker Testing for mCRPC; PARP Inhibitors for mCRPC (49:33) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia | Faculty Presentation 2: Available and Emerging Nontargeted Therapies for AML — Naval Daver, MD
CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia | Faculty Presentation 1: Current and Emerging Role of Biomarker-Directed Therapeutic Approaches for Patients with Acute Myeloid Leukemia (AML) — Courtney D DiNardo, MD, MSCE
CME information and select publications

Featuring perspectives from Dr Naval Daver and Dr Courtney D DiNardo, including the following topics:
Introduction (0:00) Available and Emerging Nontargeted Therapies for Acute Myeloid Leukemia (AML) —Dr Daver (6:47) Current and Emerging Role of Biomarker-Directed Therapeutic Approaches for Patients with AML —Dr DiNardo (32:58) CME information and select publications

Featuring perspectives from Ms Marianne J Davies, Dr Alexander I Spira, Ms Jillian Thompson and Dr Helena Yu, including the following topics:
Introduction (0:00) The Importance of EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) (7:02) The Role of Osimertinib in Managing Localized and Locally Advanced NSCLC with an EGFR Mutation (11:58) Established First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (32:38) Newly Approved and Promising Investigational Approaches to First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (37:45) Common Toxicities Associated with Amivantamab (45:07) The Current and Future Management of Progressive NSCLC with an EGFR Mutation (55:06) Tolerability and Other Practical Considerations with HER3-DXd (1:01:06) Treatment for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations (1:18:26) CME information and select publications

Featuring perspectives from Dr Julia Foldi, Dr Laura Huppert, Dr Rita Nanda, Dr Saba Shaikh and Dr Sara M Tolaney, including the following topics:
Introduction: Overview of metastatic triple-negative breast cancer (mTNBC) 
Current and emerging strategies for patients with mTNBC (0:00) First-line treatment of mTNBC — Chemotherapy with or without immunotherapy 
Case: A woman in her early 60s with a history of well-controlled HIV is diagnosed with mTNBC — Dr Shaikh (6:10) Case: A woman in her mid 40s with de novo mTNBC — Dr Huppert (20:41) Case: A woman in her late 50s with mTNBC receives up-front pembrolizumab/chemotherapy — Dr Foldi (42:15) Antibody-drug conjugates (ADCs) in the management of mTNBC 
ADCs in the management of mTNBC; sequencing of these agents and ongoing investigations (51:45) Case: A woman in her early 50s with mTNBC receives first-line chemotherapy/immune checkpoint inhibitor followed by sacituzumab govitecan — Dr Shaikh (1:05:32) Case: A woman in her late 30s with mTNBC receives sacituzumab govitecan — Dr Huppert (1:14:21) Case: A woman in her early 40s with mTNBC (IHC 1+) with sacituzumab govitecan-intolerant disease experiences an excellent response to trastuzumab deruxtecan (T-DXd) — Dr Foldi (1:27:30) Case: A woman in her mid 50s with HER2-low metastatic breast cancer receives T-DXd — Dr Shaikh (1:42:00) PARP inhibition for the treatment of mTNBC 
Efficacy and tolerability of olaparib in patients with a germline BRCA mutation and HER2-negative breast cancer  (1:49:49) Case: A woman in her mid 30s with mTNBC receives olaparib — Dr Foldi (1:54:28) Case: A woman in her mid 60s with mTNBC and a BRCA mutation receives olaparib — Dr Huppert (1:59:11) Case: A woman in her mid 40s with a BRCA1 germline mutation and mTNBC receives olaparib — Dr Shaikh (2:03:45) CME information and select publications